Kinevant Sciences Employee Directory
Biotechnology ResearchNew York, United States11-50 Employees
Kinevant Sciences is a biotechnology research company based in New York, focused on developing therapies for rare inflammatory diseases. Its lead candidate, namilumab, is an investigational monoclonal antibody being studied for sarcoidosis, with the aim of addressing disease processes by targeting GM-CSF. The company emphasizes safety, tolerability, and accessibility in its disease-modifying approaches for underserved patient populations. The firm has two actively enrolling clinical trials exploring namilumab as a treatment for sarcoidosis, including pulmonary sarcoidosis. A notable development in 2022 was the first patient dosed in the Phase 2 study of namilumab for pulmonary sarcoidosis. As a smaller organization within the biotechnology research sector, Kinevant operates from New York and serves patients and clinicians seeking new options for inflammatory diseases.